NCT00434577 - Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects | Biotech Hunter

Enrollment

715

Participants

Timeline

Start Date

February 14, 2007

Primary Completion Date

October 4, 2007

Study Completion Date

July 14, 2010

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

Herpes Zoster vaccine GSK1437173A Low Dose

Single or two-dose intramuscular injection.

BIOLOGICAL

Herpes Zoster vaccine GSK1437173A Medium Dose

Single or two-dose intramuscular injection.

BIOLOGICAL

Herpes Zoster vaccine GSK1437173A High Dose

Single or two-dose intramuscular injection.

BIOLOGICAL

Herpes Zoster vaccine GSK1437173A Modified

Single or two-dose intramuscular injection.

BIOLOGICAL

Placebo

Single intramuscular injection

Trial Locations (11)

13347

GSK Investigational Site, Berlin

30625

GSK Investigational Site, Hanover

45359

GSK Investigational Site, Essen

51069

GSK Investigational Site, Cologne

68161

GSK Investigational Site, Mannheim

97070

GSK Investigational Site, Würzburg

500 01

GSK Investigational Site, Hradec Králové

1018 WT

GSK Investigational Site, Amsterdam

3011 EN

GSK Investigational Site, Rotterdam

SE-631 88

GSK Investigational Site, Eskilstuna

SE-751 85

GSK Investigational Site, Uppsala